Morgans Senior Analyst Scott Power caught up with Robert Proulx, Chief Executive Officer of Imagion Biosystems, who explained with he joined the company and the technology behind it.
Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review
June 3, 2026
Imagion Biosystems, Ltd. (ASX: IBX) has announced that the US Food and Drug Administration (FDA) completed its review of the company’s investigational new drug (IND)